Shots:

• The NMPA has approved a P-I/II SWATCH dose-escalation & dose-expansion study that evaluates the safety, tolerability, and preliminary efficacy of selinexor in combination with the R2 regimen of lenalidomide + rituximab for rrDLBCL and rriNHL who are not eligible for HDC or ASCT. The study was conducted at 10 centers across China
• The 1EPs of the study are the MTD and RP2D as determined by the DLT observed in the dose-escalation phase along with other key safety measures. The 2EPs include ORR, PFS & DoR of the SR2 regimen as assessed acc. to the Lugano 2014 criteria (Cheson, 2014) for the assessment of lymphoma
• Selinexor has already received the US FDA's approval for the treatment of rrDLBC

Ref: Antengene | Image: Antengene